Stem Cell News

BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.

As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.

Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.

Mesoblast to Enroll 300 Patients in COVID-19 Trial of Stem Cell Therapy Remestemcel-L

May 6, 2020 By Cade Hildreth, Founder & President 1 Comment

Phase 2/3 Randomized Controlled Trial of Remestemcel-L in 300 Patients With COVID-19 Acute Respiratory Distress Syndrome Begins Enrollment

NEW YORK, April 30, 2020 — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced a Phase 2/3 randomized, placebo-controlled trial to rigorously confirm whether its allogeneic mesenchymal stem cell therapy remestemcel-L provides a survival benefit in moderate/severe acute respiratory distress syndrome (ARDS) due to COVID-19 has commenced enrollment. [Read more…]

Stem Cells for Coronavirus: Could Cells Be The Cure?

May 6, 2020 By Cade Hildreth, Founder & President 1 Comment

Coronavirus disease (COVID-19) is an emerging global pandemic that is threatening the viability of healthcare systems worldwide. The virus responsible for the disease is also known as severe acute respiratory syndrome coronavirus 2 and abbreviated as SARS-CoV-2. The eruption started in China on December 29, 2019 and by March 2020 it was reported that it had spread to several countries across the world. [Read more…]

Aspire Health Science Announces Strategic Partnership with NeoProgen for Development and Manufacturing of NeoProgen’s cell-based therapy

May 6, 2020 By Cade Hildreth, Founder & President Leave a Comment

ORLANDO, Florida, May 6th, 2020– Aspire Health Science, LLC (the “Company” or “Aspire”), an FDA registered GMP manufacturing facility specialized in the research, development, and manufacturing of cell-based therapies, is pleased to announce a collaboration with NeoProgen, Inc.

NeoProgen, a Baltimore-based company led by Medtech entrepreneur Bill Niland, is a preclinical stage therapeutics company specializing in the development of novel cellbased cardiac therapies for heart regeneration. Similar to Mr. Niland’s earlier venture with Harpoon Medical, NeoProgen has origins in research at the University of Maryland, Baltimore. That is where Dr. Sunjay Kaushal, a leading pediatric cardiac surgeon, discovered that a specific kind of neonatal cardiac progenitor/ stem cells (nCPCs), obtained from discarded cardiac tissue biopsies, are extremely effective in regenerating muscle tissue in the heart. [Read more…]

Organicell Announces FDA Approval of IND Application for the Treatment of SARS Due to COVID-19

May 5, 2020 By Cade Hildreth, Founder & President 2 Comments

MIAMI, May 05, 2020 — Organicell Regenerative Medicine, Inc. (OTCBB:BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its lead product, Organicell Flow, for patients diagnosed with moderate to severe acute respiratory syndrome (SARS) due to COVID-19 infection. [Read more…]

BioStem Technologies Announces Corporate Update on Company Direction

April 29, 2020 By Cade Hildreth, Founder & President Leave a Comment

Pompano Beach, FL, April 29th, 2020 — BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”) a leading life sciences company specializing in perinatal tissue-based allografts for use in regenerative therapies, today announced a corporate update on the Company’s direction.

The Company announced that it embarked on a new initiative to define its two distinct business pillars, BioStem Technologies and BioStem Life Sciences. The new strategic focus of BioStem Technologies is to identify, develop and market the life changing regenerative biologics, formally spearheaded by BioStem Life Sciences. This includes an all new biologic therapeutic pipeline focused on Acute Respiratory Distress Syndrome (ARDS) and Osteoarthritis (OA). BioStem Technologies will also assume the sales and distribution of the RHEO™, VENDAJE™, VENDAJE™ AC, and VENDAJE™ OPTIC brands. [Read more…]